Company: CERO
Filing Date: 2025-05-02
Form Type: PRER14A
Source: 0001213900-25-039149
Chunk: 20

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-02
Form: PRER14A
Chunk 20
---
 that we had regained compliance with the Bid Price Requirement and we have been moved to the Nasdaq Capital Market, as required by the Nasdaq Panel. However, through April23, 2025, the closing bid price of our Common Stock was below the $1.00 Bid Price Requirement for 26 consecutive trading days before such closing bid price exceeded $1.00 on April24, 2025. Under applicable Nasdaq rules, if the Company fails to satisfy the Bid Price Requirement again for at least 30 consecutive trading days prior to the first anniversary of the Company’s one -for-100reverse stock effectuated on January 8, 2025, the Company would be ineligible for a 180 -daycompliance period to permit curing such deficiency. Accordingly, as there can be no assurance that the closing bid price will not be below $1.00 in the future, the Company’s Board believes that it is in the best interests of the Company and its stockholders to proactively seek and obtain stockholder approval of an authorization to consummate an additional Reverse Stock Split. Failure to approve the Reverse Stock Split may have serious, adverse effects on the Company and its stockholders. Our Common Stock could be delisted from Nasdaq because shares of our Common Stock may trade below the requisite $1.00 per share price needed to comply with the listing requirements of Nasdaq and maintain our listing. Our shares may then be quoted on the OTC Bulletin Board or other small trading markets, which are generally considered to have less volume and be less efficient markets. We believe an investor likely would find it less convenient to sell, or to obtain accurate quotations in seeking to buy, our Common Stock on an over -the-countermarket. Many investors likely would not buy or sell our Common Stock due to difficulty in accessing over -the-countermarkets, policies preventing them from trading in securities not listed on a national exchange, or other reasons. In that event, the Common Stock could trade thinly as a microcap or penny stock, adversely decrease to nominal levels of trading and may be avoided by retail and institutional investors, resulting in the impaired liquidity of our Common Stock. 8 As of the Record Date, our Common Stock closed at $0.7300 per share on Nasdaq. The Reverse Stock Split, if effected, should have the immediate effect of increasing the price of our Common Stock as reported on Nasdaq, therefore reducing the risk that our Common Stock could be delisted from Nasdaq. However, we cannot assure you that the price of our